Laversin S - Search Results

1

A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.

Papadakis E, Robson N, Yeomans A, Bailey S, Laversin S, Beers S, Sayan AE, Ashton-Key M, Schwaiger S, Stuppner H, Troppmair J, Packham G, Cutress R. Papadakis E, et al. Among authors: laversin s. Oncotarget. 2016 Apr 5;7(14):18851-64. doi: 10.18632/oncotarget.7944. Oncotarget. 2016. PMID: 26958811 Free PMC article.

2

Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma.

Birts CN, Savva C, Laversin SA, Lefas A, Krishnan J, Schapira A, Ashton-Key M, Crispin M, Johnson PWM, Blaydes JP, Copson E, Cutress RI, Beers SA. Birts CN, et al. Among authors: laversin sa. Sci Rep. 2022 May 24;12(1):7802. doi: 10.1038/s41598-022-11696-6. Sci Rep. 2022. PMID: 35610242 Free PMC article.

3

The effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells.

Banerjee A, Arvinrad P, Darley M, Laversin SA, Parker R, Rose-Zerilli MJJ, Townsend PA, Cutress RI, Beers SA, Houghton FD, Birts CN, Blaydes JP. Banerjee A, et al. Among authors: laversin sa. Oncotarget. 2018 May 1;9(33):23274-23288. doi: 10.18632/oncotarget.25299. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796188 Free PMC article.

4

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS. Tutt AL, et al. Among authors: laversin sa. J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28. J Immunol. 2015. PMID: 26512139

5

A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics.

Harner-Foreman N, Vadakekolathu J, Laversin SA, Mathieu MG, Reeder S, Pockley AG, Rees RC, Boocock DJ. Harner-Foreman N, et al. Among authors: laversin sa. Sci Rep. 2017 Jan 17;7:40633. doi: 10.1038/srep40633. Sci Rep. 2017. PMID: 28094783 Free PMC article.

6

Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?

Dunning NL, Laversin SA, Miles AK, Rees RC. Dunning NL, et al. Among authors: laversin sa. Cancer Immunol Immunother. 2011 Aug;60(8):1181-93. doi: 10.1007/s00262-011-1065-8. Epub 2011 Jun 19. Cancer Immunol Immunother. 2011. PMID: 21688178 Free PMC article. Review.

7

Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells.

Laversin SA, Phatak VM, Powe DG, Li G, Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I, McArdle SE, Rees RC. Laversin SA, et al. Genes Chromosomes Cancer. 2013 Mar;52(3):316-29. doi: 10.1002/gcc.22031. Epub 2012 Dec 8. Genes Chromosomes Cancer. 2013. PMID: 23225347

8

Identification of immunogenic MHC class II Tyrosinase-derived peptides using HLA-DR1 and HLA-DR4 transgenic mice.

Horton RB, Laversin SA, Reeder SP, Rees RC, McArdle SE. Horton RB, et al. Among authors: laversin sa. Protein Pept Lett. 2007;14(5):455-60. doi: 10.2174/092986607780782768. Protein Pept Lett. 2007. PMID: 17584170

9

Improving the transparency of health information found on the internet through the honcode: a comparative study.

Laversin S, Baujard V, Gaudinat A, Simonet MA, Boyer C. Laversin S, et al. Stud Health Technol Inform. 2011;169:654-8. Stud Health Technol Inform. 2011. PMID: 21893829

10

Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model.

Vafadar-Isfahani B, Laversin SA, Ahmad M, Ball G, Coveney C, Lemetre C, Kathleen Miles A, van Schalkwyk G, Rees R, Matharoo-Ball B. Vafadar-Isfahani B, et al. Among authors: laversin sa. Proteomics Clin Appl. 2010 Sep;4(8-9):682-96. doi: 10.1002/prca.200900218. Proteomics Clin Appl. 2010. PMID: 21137086

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters